A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder and Narcan® 4 mg/0.1 mL Nasal Spray Under Fasting Conditions
Latest Information Update: 14 Jun 2022
At a glance
- Drugs Naloxone (Primary) ; Naloxone
- Indications Opioid-related disorders
- Focus Pharmacokinetics; Registrational
- Sponsors Nasus Pharma
- 01 May 2022 Results published in the Pharmaceutical Research
- 12 Oct 2021 Status changed from recruiting to completed.
- 13 Apr 2021 Results presented in the Nasus Pharma Media Release.